Development Of Transdermal Patch of Caffeine for Alertness Enhancement

Nikita Sanjay Salekar, Gaikwad Kirti Sudhakar, Ubale Nikita Sudhakar, Najan Sumit Suresh, Shirsath Rameshwar Vishnu
Shri Laxmanrao Trymbakrao Nakade Pharmacy College Dhorjalgaon Ne

Abstract- Fatigue, drowsiness, and reduced alertness are common problems affecting students, professionals, and shift workers. Caffeine is a widely used central nervous system stimulant that improves wakefulness, attention, and cognitive performance. Conventional oral caffeine formulations provide rapid stimulation but produce fluctuations in plasma concentration, gastrointestinal irritation, and dependence. Therefore, a controlled drug delivery system such as transdermal patch can provide sustained drug release and improved patient compliance. The present study aimed to develop and evaluate a transdermal patch containing caffeine for alertness enhancement. The patches were prepared using solvent casting method with suitable polymers and plasticizers. The prepared patches were evaluated for thickness, weight variation, folding endurance, moisture content, drug content, in-vitro drug release, and skin permeation. The results indicated that the developed patch showed uniform physicochemical properties and sustained drug release for 24 hours. The study concludes that transdermal caffeine patch can be considered a promising alternative to oral caffeine formulations for prolonged alertness enhancement.

Keywords- Caffeine, Transdermal patch, Alertness, Sustained release, CNS stimulant, Drug delivery system

I.INTRODUCTION

Alertness is the state of mental wakefulness and attention required for optimal cognitive performance. Lack of sleep, stress, prolonged working hours, and shift work commonly lead to fatigue and reduced alertness [1]. Decreased alertness affects productivity, reaction time, and decision-making ability and may increase risk of accidents.



Figure 1: Mechanism of transdermal drug delivery

Caffeine is one of the most widely consumed psychoactive substances in the world. It acts as a central nervous system stimulant primarily by antagonizing adenosine receptors, resulting in increased neuronal activity and release of neurotransmitters such as dopamine and norepinephrine [2]. Caffeine improves attention, concentration, mood, and physical performance.

Conventional oral caffeine formulations provide rapid onset of action but have limitations such as gastric irritation, short duration of effect, repeated dosing, and fluctuating plasma levels [3]. A controlled drug delivery system is therefore required to maintain steady drug concentration for prolonged alertness.



Figure 2: Chemical structure of caffeine

Transdermal drug delivery systems (TDDS) deliver drugs through the skin into systemic circulation and offer several advantages such as avoidance of first-pass metabolism, sustained release, improved bioavailability, and better patient compliance [4]. Transdermal patches are especially useful for drugs requiring prolonged therapeutic effect.

Caffeine possesses suitable physicochemical properties such as low molecular weight and moderate lipophilicity which makes it a potential candidate for transdermal delivery [5]. Therefore, development of caffeine transdermal patch can provide controlled stimulation and improved therapeutic performance.

AIM OF THE STUDY

To develop and evaluate a transdermal patch of caffeine for sustained alertness enhancement.

OBJECTIVES OF THE STUDY

1. To formulate caffeine transdermal patches using suitable polymers.
2. To evaluate physicochemical properties of patches.
3. To study in-vitro drug release and permeation.
4. To determine stability of formulation.
5. To assess suitability of patch for prolonged alertness.

II.REVIEW OF LITERATURE

Transdermal drug delivery systems (TDDS) have gained significant importance in recent years due to their ability to provide controlled drug release and improve patient compliance. These systems avoid

first-pass metabolism and maintain steady plasma drug concentration. Prausnitz et al. reported that transdermal patches are effective for delivering drugs requiring prolonged therapeutic effect and reduced dosing frequency [6].

Caffeine is a methylxanthine derivative widely used as a central nervous system stimulant. Nehlig et al. explained that caffeine improves alertness by blocking adenosine receptors in the brain, resulting in increased neuronal firing and release of neurotransmitters [7]. The study confirmed its effectiveness in improving cognitive performance and reducing fatigue.



Figure 3: Skin permeation pathways in transdermal drug delivery

Oral caffeine administration causes rapid absorption followed by rapid elimination leading to fluctuating plasma levels. Bonati et al. reported that sustained drug delivery systems can overcome these fluctuations and provide prolonged stimulation [8].

Several researchers have explored transdermal delivery of CNS active drugs. Guy and Hadgraft described that drugs with moderate lipophilicity and low molecular weight are suitable candidates for transdermal administration [9]. Caffeine meets these criteria, making it an ideal drug for TDDS.

A study by Benson formulated transdermal patches and observed improved bioavailability and controlled release compared to oral formulations [10]. Similarly, Patel et al. developed polymeric patches and demonstrated sustained drug release for 24 hours [11].

Kumar et al. prepared transdermal patches using hydrophilic polymers and reported uniform thickness, good folding endurance, and stable drug release profile [12].

These studies indicate that transdermal patches can provide prolonged drug delivery and improved therapeutic performance. However, limited research is available on transdermal caffeine patches specifically designed for alertness enhancement. Therefore, the present study was undertaken to develop and evaluate caffeine transdermal patch.

Sr. No.	Author	Year	Study	Major Findings
1	Prausnitz et al.	2004	TDDS	Controlled release
2	Nehlig et al.	1992	Caffeine pharmacology	CNS stimulation

3	Bonati et al.	1982	Sustained delivery	Stable plasma levels
4	Guy & Hadgraft	2003	Skin permeation	Suitable drug properties
5	Benson	2005	Patch formulation	Improved bioavailability
6	Kumar et al.	2010	Polymeric patch	Sustained release

Table 1: Summary of Previous Studies on Transdermal Drug Delivery

III.MATERIALS AND METHODS

3.1 Materials

Caffeine (Active Pharmaceutical Ingredient), Hydroxypropyl Methylcellulose (HPMC), Polyvinyl Alcohol (PVA), Polyethylene Glycol 400 (PEG-400), Glycerin (plasticizer), Dimethyl Sulfoxide (penetration enhancer), Ethanol, Distilled water, Phosphate buffer pH 7.4, Cellophane membrane, Whatman filter paper, and standard laboratory glassware were used in the study [13].



Figure 4: Preparation of caffeine transdermal patch by solvent casting method

3.2 Method of Preparation

Solvent Casting Method

Transdermal patches were prepared using solvent casting method.

1. Required quantity of polymer (HPMC/PVA) was dissolved in distilled water.
2. Caffeine was dissolved in ethanol separately.
3. Plasticizer (PEG-400/Glycerin) and penetration enhancer were added.
4. Drug solution was mixed with polymer solution under continuous stirring.
5. The solution was poured into glass petri plates and dried at room temperature for 24 hours.
6. Dried patches were carefully peeled and cut into uniform size (2×2 cm).

3.3 Formulation Composition

Ingredient	F1 (%)	F2 (%)	F3 (%)	Function
Caffeine	5	5	5	Active drug
HPMC	30	35	40	Polymer
PVA	20	15	10	Film former
PEG-400	10	10	10	Plasticizer
DMSO	5	5	5	Penetration enhancer
Distilled Water	q.s	q.s	q.s	Solvent

Table 2: Composition of Caffeine Transdermal Patch

3.4 Evaluation of Transdermal Patches

3.4.1 Thickness

Measured using digital micrometer at three different positions.

3.4.2 Weight Variation

Individual patches were weighed and average weight calculated.

3.4.3 Folding Endurance

Patch was folded repeatedly at the same place until it broke.

3.4.4 Moisture Content

Patches were weighed and stored in desiccator; percentage moisture loss calculated.

3.4.5 Drug Content

Patch was dissolved in phosphate buffer and analyzed using UV spectrophotometer at λmax 273 nm [14].

3.5 In-Vitro Drug Release Study

Franz diffusion cell apparatus was used. Cellophane membrane separated donor and receptor compartments. Phosphate buffer (pH 7.4) maintained at 37°C was used as receptor medium. Samples were withdrawn at regular intervals and analyzed spectrophotometrically [15].



Figure 5: In-vitro drug release study using Franz diffusion cell

3.6 Stability Study

Prepared patches were stored at 25°C and 40°C for 30 days and evaluated for physical changes and drug content variation [16].

IV.RESULTS AND DISCUSSION

4.1 Physicochemical Evaluation of Patches

The prepared caffeine transdermal patches were smooth, flexible, and uniform in appearance. No air bubbles or cracks were observed.

Parameter	F1	F2	F3
Thickness (mm)	0.24 ± 0.02	0.26 ± 0.01	0.29 ± 0.02
Weight (mg)	215 ± 5	225 ± 4	238 ± 6
Folding Endurance	245	278	310
Moisture Content (%)	2.8	2.5	2.3
Drug Content (%)	96.4	97.8	98.6

Table 3: Evaluation of Transdermal Patches

Observation: F3 formulation showed highest folding endurance and uniform drug content.

4.2 In-Vitro Drug Release Study

The cumulative percentage drug release was determined for 24 hours.

Time (hrs)	F1 (%)	F2 (%)	F3 (%)
1	12	10	8
2	22	18	15
4	38	32	28
6	52	45	40
8	64	58	52
12	78	72	66
24	95	90	84

Table 4: Cumulative % Drug Release



Graph 1: Cumulative % Drug Release vs Time

4.3 Discussion

The physicochemical evaluation showed that all formulations possessed acceptable mechanical properties. Increase in polymer concentration resulted in increased thickness and folding endurance.

The in-vitro release study demonstrated sustained release of caffeine over 24 hours. F1 showed faster release due to lower polymer concentration, whereas F3 exhibited controlled release pattern due to higher polymer content.

Sustained release from transdermal patch ensures steady plasma concentration of caffeine, reducing fluctuations associated with oral administration. The formulation can therefore provide prolonged alertness without frequent dosing.

The results confirm that caffeine is a suitable candidate for transdermal delivery and that the prepared patch meets required pharmaceutical standards.

V.CONCLUSION

The present study successfully developed and evaluated a caffeine transdermal patch using solvent casting method. The prepared patches exhibited uniform thickness, satisfactory folding endurance, acceptable drug content, and sustained drug release for 24 hours.

The developed transdermal system can serve as a promising alternative to oral caffeine formulations for prolonged alertness enhancement.

VI.FUTURE SCOPE

- In-vivo pharmacokinetic study
- Skin irritation study
- Clinical evaluation in shift workers
- Commercial scale-up development

REFERENCES

[1] Lim J, Dinges DF. A meta-analysis of the impact of short-term sleep deprivation on cognitive variables. *Psychological Bulletin*. 2010;136(3):375–389.

[2] Nehlig A, Daval JL, Debry G. Caffeine and the central nervous system: mechanisms of action, biochemical, metabolic and psychostimulant effects. *Brain Research Reviews*. 1992;17(2):139–170.

[3] Bonati M, Latini R, Tognoni G, Young JF, Garattini S. Caffeine disposition after oral doses. *Clinical Pharmacology and Therapeutics*. 1982;32(1):98–106.

[4] Prausnitz MR, Langer R. Transdermal drug delivery. *Nature Biotechnology*. 2008;26(11):1261–1268.

[5] Hadgraft J. Skin, the final frontier. *International Journal of Pharmaceutics*. 2001;224(1–2):1–18.

[6] Prausnitz MR, Mitragotri S, Langer R. Current status and future potential of transdermal drug delivery. *Nature Reviews Drug Discovery*. 2004;3(2):115–124.

[7] Benson HA. Transdermal drug delivery: penetration enhancement techniques. *Current Drug Delivery*. 2005;2(1):23–33.

[8] Guy RH, Hadgraft J. *Transdermal Drug Delivery*. 2nd ed. New York: Marcel Dekker; 2003.

[9] Barry BW. Novel mechanisms and devices to enable successful transdermal drug delivery. *European Journal of Pharmaceutical Sciences*. 2001;14(2):101–114.

[10] Patel RP, Patel G, Baria AH. Formulation and evaluation of transdermal patches. *International Journal of PharmTech Research*. 2009;1(4):1194–1199.

[11] Kumar R, Philip A. Modified transdermal technologies. *Indian Journal of Pharmaceutical Sciences*. 2007;69(2):199–207.

[12] Aulton ME, Taylor K. *Aulton's Pharmaceutics: The Design and Manufacture of Medicines*. 5th ed. London: Elsevier; 2018.

[13] Allen LV, Ansel HC. *Pharmaceutical Dosage Forms and Drug Delivery Systems*. 10th ed. Philadelphia: Lippincott Williams & Wilkins; 2014.

[14] Sinko PJ. *Martin's Physical Pharmacy and Pharmaceutical Sciences*. 6th ed. Philadelphia: Lippincott Williams & Wilkins; 2011.

[15] Higuchi T. Mechanism of sustained-action medication. *Journal of Pharmaceutical Sciences*. 1963;52(12):1145–1149.

[16] Jain NK. *Controlled and Novel Drug Delivery*. New Delhi: CBS Publishers; 2012.

[17] United States Pharmacopeia (USP 43–NF 38). Rockville: United States Pharmacopeial Convention; 2020.

[18] World Health Organization. *WHO Guidelines for Stability Testing of Pharmaceutical Products*. Geneva: WHO; 2009.
[19] Rowe RC, Sheskey PJ, Quinn ME. *Handbook of Pharmaceutical Excipients*. 7th ed. London: Pharmaceutical Press; 2012.
[20] Rang HP, Dale MM, Ritter JM, Flower RJ. *Rang and Dale's Pharmacology*. 8th ed. London: Elsevier; 2016.
[21] Katzung BG. *Basic and Clinical Pharmacology*. 14th ed. New York: McGraw-Hill; 2018.
[22] Shargel L, Yu ABC. *Applied Biopharmaceutics and Pharmacokinetics*. 7th ed. New York: McGraw-Hill; 2016.
[23] Williams AC, Barry BW. Penetration enhancers. *Advanced Drug Delivery Reviews*. 2012;64:128–137.
[24] Chien YW. *Novel Drug Delivery Systems*. 2nd ed. New York: Marcel Dekker; 1992.
[25] Guy RH. Current status and future prospects of transdermal drug delivery. *Pharmaceutical Research*. 1996;13(12):1765–1769.
[26] Lippincott Williams & Wilkins. *Remington: The Science and Practice of Pharmacy*. 22nd ed. Philadelphia: LWW; 2012.
[27] Bonnet MH, Arand DL. Caffeine use as a model of acute and chronic insomnia. *Sleep Medicine Reviews*. 2007;11(1):25–34.
[28] Institute of Medicine. *Caffeine for the Sustainment of Mental Task Performance*. Washington, DC: National Academies Press; 2001.
[29] Food and Drug Administration (FDA). *Guidance for Industry: Transdermal and Topical Delivery Systems*. Silver Spring: FDA; 2019.
[30] Petersen RC. Cognitive enhancement and stimulants: clinical implications. *Journal of Internal Medicine*. 2004;256(3):183–194.